Application

Analytes: ARG1, GSTα, SDH 5′-NT/CD73, Malate dehydrogenase 1 (MDH1) Recommended Sample type: serum, plasma, and tissue culture supernatants Recommended Sample dilution: 1:5 serum or plasma samples. Tissue culture supernatants may require dilution as well. Assay Run Time: One day or Overnight Research Category: Toxicity

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Features and Benefits

Design your multiplex kit by choosing available analytes within this panel.

General description

Drug toxicity is the leading cause of acute liver failure in the United States. Patients with liver damage generally display elevated amounts of specific liver proteins in serum; these proteins can serve as biomarkers of drug-related liver toxicity. Monitoring these biomarkers can greatly help clinicians avoid drug-induced liver failure. Performing laboratory tests to characterize the side effects of potential therapeutics is an essential part of drug development. The search for sensitive, organ-specific toxicity biomarkers is complemented by the development of novel assays to measure these critical analytes. Liver-Type Arginase 1 (ARG1), α-glutathione Stransferase (GSTα), Malate dehydrogenase 1 (MDH1) and Sorbitol Dehydrogenase (SDH) are biomarkers listed in the Predictive Safety Testing Consortium (PSTC) project pipeline which have a strong translational role in drug safety testing. 5′-Nucleotidase/CD73 (5’;-NT) is a traditional biomarker recognized by both the Food and Drug Administration (FDA) and its European counterpart, the European Medicines Agency (EMA). The MILLIPLEX^® Human Liver Injury Panel contains all the components necessary to simultaneous quantify the following 5 analytes in serum and plasma samples: Liver-Type Arginase 1 (ARG1)* Malate dehydrogenase 1 (MDH1)* α-glutathione S-transferase (GSTα)* Sorbitol Dehydrogenase (SDH)* 5′-Nucleotidase/CD73 (5’;-NT) *ARG1, GSTα, and SDH are biomarkers listed in the Predictive Safety Testing Consortium (PSTC) project pipeline which have a strong translational role in drug safety testing. The MILLIPLEX^® portfolio offers the broadest selection of analytes across a wide range of disease states and species. Once the analytes of interest have been identified, you can rely on the quality that we build into each kit to produce results you can trust. In addition to the assay characteristics listed in the protocol, other performance criteria evaluated during the validation process include: cross-reactivity, dilution linearity, kit stability, and sample behavior (e.g. detectability and stability). Panel Type: Toxicity

Legal Information

xMAP is a registered trademark of Luminex Corp

Luminex is a registered trademark of Luminex Corp

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Sensitivity: Please see kit protocol for individual assay sensitivities.

Please contact Technical Service for linearity of dilution.

Packaging

Everything you need in a single kit.

Specificity

Cross ReactivtyThere was no or negligible cross-reactivity between the antibodies for an analyte and any of the other analytes within a panel.

Storage and Stability

Recommended storage for kit components is 2 - 8°C.